Enhanced efflux of cholesterol from ABCA1-expressing macrophages to serum from type IV hypertriglyceridemic subjects


      Since elevated plasma triglycerides (TGs) are an independent cardiovascular risk factor, we have compared the cholesterol efflux potential of sera from asymptomatic hypertriglyceridemic (HTG) type IIb, type IV or normolipidemic (NLP) individuals using two different cell systems. In both type IIb and IV HTG, the efflux of cholesterol from SR-BI-rich Fu5AH cells was similar to that obtained with NLP. The maintenance of efflux efficiency in spite of reduced HDL-cholesterol levels can be mainly attributed to the relative enrichment of HDL with phospholipid. In the J774 macrophage cell system, pretreatment with cAMP, which upregulates ABCA1, induced a markedly higher increase in efflux to type IV sera compared with type IIb or NLP. In addition, type IV sera exhibited two-fold higher pre-β HDL relative concentration (percentage of total apo AI) compared with NLP. Moreover, positive correlations were established between ABCA1-mediated efflux and the serum pre-β HDL levels or TG concentrations. Thus, the hyperTGemia is associated with a higher fraction of apo AI recovered as pre-β HDL which appear to be partly responsible for enhanced efflux obtained upon the cAMP stimulation of J774 cells. In conclusion, we demonstrated for the first time that the ABCA1-expressing J774 cell system is responsive to the percent of apo AI present in human serum as pre-β HDL. Our results suggest that high-plasma TG, accompanied by low HDL may not result in an impaired cholesterol efflux capacity.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Hokanson J.E.
        • Austin M.A.
        Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies.
        J. Cardiovasc. Risk. 1996; 3: 213-219
        • Austin M.A.
        Epidemiology of hypertriglyceridemia and cardiovascular disease.
        Am. J. Cardiol. 1999; 83: 13F-16F
        • Sattar N.
        • Petrie J.R.
        • Jaap A.J.
        The atherogenic lipoprotein phenotype and vascular endothelial dysfunction.
        Atherosclerosis. 1998; 138: 229-235
        • Lamarche B.
        • Despres J.P.
        • Pouliot M.C.
        • Prud’homme D.
        • Moorjani S.
        • Lupien P.J.
        • et al.
        Metabolic heterogeneity associated with high plasma triglyceride or low HDL cholesterol levels in men.
        Arterioscler Thromb. 1993; 13: 33-40
        • Stein O.
        • Stein Y.
        Atheroprotective mechanisms of HDL.
        Atherosclerosis. 1999; 144: 285-301
        • von Eckardstein A.
        • Nofer J.R.
        • Assmann G.
        High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport.
        Arterioscler. Thromb. Vasc. Biol. 2001; 21: 13-27
        • Wilson P.W.
        • Abbott R.D.
        • Castelli W.P.
        High density lipoprotein cholesterol and mortality. The Framingham Heart Study.
        Atherosclerosis. 1998; 8: 737-741
        • Cavallero E.
        • Brites F.
        • Delfly B.
        • Nicolaı̈ew N.
        • Decossin C.
        • De Geitere C.
        • Fruchart J.C.
        • et al.
        Abnormal reverse cholesterol transport in controlled type II diabetic patients. Studies on fasting and postprandial LpA-I particles.
        Arterioscler Thromb. Vasc. Biol. 1995; 15: 2130-2135
        • Brites F.D.
        • Bonavita C.D.
        • De Geitere C.
        • Clöes M.
        • Delfly B.
        • Yael M.J.
        • et al.
        Alterations in the main steps of reverse cholesterol transport in male patients with primary hypertriglyceridemia and low HDL-cholesterol levels.
        Atherosclerosis. 2000; 152: 181-192
        • Rothblat G.H.
        • de la Llera-Moya M.
        • Atger V.
        • Kellner-Weibel G.
        • Williams D.L.
        • Phillips M.C.
        Cell cholesterol efflux: integration of old and new observations provides new insights.
        J. Lipid Res. 1999; 40: 781-796
        • Yancey P.G.
        • de la Llera-Moya M.
        • Swarnakar S.
        • Monzo P.
        • Klein S.M.
        • Connelly M.A.
        • et al.
        High density lipoprotein phospholipid composition is a major determinant of the bi-directional flux and net movement of cellular free cholesterol mediated by scavenger receptor BI.
        J. Biol. Chem. 2000; 275: 36596-36604
        • Fournier N.
        • Atger V.
        • Paul J.L.
        • Sturm M.
        • Duverger N.
        • Rothblat G.H.
        • et al.
        Human apo AIV overexpression in transgenic mice induces cAMP stimulated cholesterol efflux from J774 macrophages to whole serum.
        Arterioscler. Thromb. Vasc. Biol. 2000; 20: 1283-1292
        • Bortnick A.E.
        • Rothblat G.H.
        • Stoudt G.
        • Hoppe K.L.
        • Royer L.J.
        • Mc Neish J.
        • et al.
        The correlation of ATP-binding cassette 1 mRNA levels with cholesterol efflux from various cell lines.
        J. Biol. Chem. 2000; 275: 28634-28640
        • Oram J.F.
        • Lawn R.M.
        • Garvin M.R.
        • Wade D.P.
        ABCA1 is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages.
        J. Biol. Chem. 2000; 275: 34508-34511
        • Fournier N.
        • Cogny A.
        • Atger V.
        • Pastier D.
        • Goudouneche D.
        • Nicoletti A.
        • et al.
        Opposite effects of plasma from human apolipoprotein A-II transgenic mice on cholesterol efflux from J774 macrophages and Fu5AH hepatoma cells.
        Arterioscler Thromb. Vasc. Biol. 2002; 22: 638-643
        • Ji Y.
        • Jian B.
        • Wang N.
        • Sun Y.
        • de la Llera-Moya M.
        • Phillips M.C.
        • et al.
        Scavenger receptor BI promotes high density lipoprotein mediated cellular cholesterol efflux.
        J. Biol. Chem. 1997; 272: 20982-20985
        • de la Llera-Moya M.
        • Atger V.
        • Paul J.L.
        • Fournier N.
        • Moatti N.
        • Giral P.
        • et al.
        A cell culture system for screening human serum for ability to promote cellular cholesterol efflux: relationships between serum components and efflux, esterification and transfer.
        Arterioscler Thromb. 1994; 14: 1056-1065
        • Fournier N.
        • de la Llera-Moya M.
        • Burkey B.
        • Swaney J.
        • Paterniti J.J.
        • Moatti N.
        • et al.
        The role of HDL phospholipids in efflux of cell cholesterol to whole serum: studies with human apo AI transgenic rats.
        J. Lipid Res. 1996; 37: 1704-1711
        • Fournier N.
        • Paul J.L.
        • Atger V.
        • Cogny A.
        • Soni T.
        • de la Llera-Moya M.
        • et al.
        HDL phospholipid content and composition as a major factor determining cholesterol efflux capacity from Fu5AH cells to human serum.
        Arterioscler Thromb. Vasc. Biol. 1997; 17: 2685-2691
        • Sakr S.W.
        • Stoudt G.W.
        • Williams D.
        • Phillips M.C.
        • Rothblat G.H.
        Induction of cellular cholesterol efflux to lipid-free apolipoprotein Al by cAMP.
        Biochim. Biophys. Acta. 1999; 1438: 85-98
        • Smith J.D.
        • Miyata M.
        • Ginsberg M.
        • Grigaux C.
        • Shmookler E.
        • Plump A.S.
        Cyclic AMP induces apolipoprotein E binding activity and promotes cholesterol efflux from a macrophage cell line to apolipoprotein acceptors.
        J. Biol. Chem. 1996; 271: 30647-30655
        • Castelli W.P.
        Lipids risk factors and ischaemic heart disease.
        Atherosclerosis. 1996; 124: S1-S9
        • Gotto Jr., A.M.
        Rationale for treatment.
        Am. J. Med. 1991; 91: 315-365
        • Asztalos B.F.
        • Roheim P.S.
        • Milani R.L.
        • Lefevre M.
        • McNamara J.R.
        • Horvath K.V.
        • et al.
        Distribution of apo AI containing HDL subpopulations in patients coronary heart disease.
        Arterioscler. Thromb. Vasc. Biol. 2000; 20: 2670-2676
        • Atger V.
        • Malon D.
        • Bertiere M.C.
        • N’Diaye F.
        • Girard-Globa A.
        Cholesterol distribution between high density lipoprotein subfractions HDL2 and HDL3 determined in serum by discontinuous gradient gel electrophoresis.
        Clin. Chem. 1991; 37: 1149-1152
        • Francone O.
        • Royer L.J.
        • Haghpassand M.
        Increased pre-beta HDL levels, cholesterol efflux and LCAT-mediated esterification in mice expressing the human cholesteryl ester transfer protein (CETP) and human apolipoprotein A-I (apo AI) transgenes.
        J. Lipid Res. 1996; 37: 1268-1277
        • Le Lay S.
        • Krief S.
        • Farnier C.
        • Lefrère I.
        • Le Liepvre X.
        • Bazin R.
        • et al.
        Cholesterol, a cell size dependent signal that regulates glucose metabolism and gene expression in adipocytes.
        J. Biol. Chem. 2001; 276: 16904-16910
        • Ishida B.Y.
        • Frohlich J.
        • Fielding C.J.
        Pre-beta-migrating high density lipoprotein, quantification in normal and hyperlipidemic plasma by solid phase radioimmunoassay following electrophoretic transfer.
        J. Lipid Res. 1987; 28: 778-786
        • Neary R.H.
        • Gowland E.
        Stability of free apolipoprotein AI concentration in serum, and its measurement in normal and hyperlipidemic subjects.
        Clin. Chem. 1997; 33: 1163-1169
        • Miida T.
        • Sakai K.
        • Ozaki K.
        • Nakamura Y.
        • Yamaguchi T.
        • Tsuda T.
        • et al.
        Bezafibrate increases preβ1-HDL at the expense of HDL2b in hypertriglyceridemia.
        Arterioscler Thromb. Vasc. Biol. 2000; 20: 2428-2433
        • Fournier N.
        • Atger V.
        • Cogny A.
        • Vedie B.
        • Giral P.
        • Simon A.
        • et al.
        Analysis of the relationship between triglyceridemia and HDL-phospholipid concentrations: consequences on the efflux capacity of serum in the Fu5AH system.
        Atherosclerosis. 2001; 157: 315-323
        • Dullaart R.P.F.
        • van Tol A.
        Letter to the editor: letter in response to recent paper by Fournier et al.
        Atherosclerosis. 2002; 164: 379-380
        • Barrans A.
        • Jaspard B.
        • Barbaras R.
        • Chap H.
        • Perret B.
        • Collet X.
        Pre-beta HDL: structure and metabolism.
        Biochim. Biophys. Acta. 1996; 1300: 73-85